Delaware |
001-31756 |
13-1947195 |
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
One Church Street, Suite 302, Rockville, MD |
20850 |
(Address of Principal Executive Offices) |
(Zip Code) |
|
(a) | Financial Statements of Businesses Acquired |
Contents | Page | |
Vitarich Laboratories, Inc. Financial Statements - August 30, 2004 and |
||
Independent Auditors Report |
3 |
|
Vitarich Laboratories, Inc. Financial Statements - December 31, 2003 and |
||
Independent Auditors Report |
18 |
|
Vitarich Laboratories, Inc. Financial Statements - December 31, 2002 and |
||
Independent Auditors Report |
31 |
| ||
|
| ||
|
| ||
|
Vitarich Laboratories, Inc.
Balance Sheet
August 30, 2004 |
ASSETS |
||||
Current Assets: |
||||
Cash |
$ |
105,708 |
||
Accounts receivable, net of allowance
of $218,000 for doubtful accounts |
1,470,429 |
|||
Inventory |
3,247,177 |
|||
Other Receivables |
8,451 |
|||
Other Pre-Paid Assets |
45,794 |
|||
Deposits on Inventory |
224,000 |
|||
Deferred Taxes |
42,785 |
|||
5,144,344 |
||||
Property & Equipment: |
||||
Machinery & Equipment |
1,117,968 |
|||
Office Furniture & Fixtures |
101,694 |
|||
Leasehold Improvements |
184,682 |
|||
1,404,344 |
||||
Less accumulated depreciation |
(340,704 |
) | ||
1,063,640 |
||||
Loan Receivable - Shareholder |
34,889 |
|||
Other Deposits |
58,332 |
|||
Total Assets |
$ |
6,301,205 |
||
Liabilities and Stockholder's Equity |
||||
Current Liabilities: |
||||
Bank Overdraft |
$ |
161,604 |
||
Accounts Payable |
2,319,628 |
|||
Accrued Payroll & Payroll Taxes |
66,407 |
|||
Accrued Income Taxes |
424,561 |
|||
Accounts Payable - Affiliated Corporation |
68,170 |
|||
Accrued Expenses and Other Current Liabilities |
275,687 |
|
Vitarich Laboratories, Inc.
Balance Sheet
August 30, 2004
(Continued) |
||||
Loan Payable -Shareholder |
515,618 |
|||
Current Portion of Notes Payable |
574,281 |
|||
Current Portion of Obligations under Capital Leases |
100,505 |
|||
4,506,461 |
||||
Other Liabilities |
||||
Notes Payable, net of Current Portion |
54,808 |
|||
Obligations Under Capital leases, net of Current Portions |
317,571 |
|||
Deferred Taxes |
192,561 |
|||
|
||||
564,940 |
||||
Stockholder's Equity |
||||
Common Stock, $1 Par Value, |
||||
100 shares authorized, 93 issued, and outstanding |
93 |
|||
Additional Paid -in-Capital |
77 |
|||
Retained Earnings |
1,229,634 |
|||
1,229,804 |
||||
Total Liabilities and Stockholder's Equity |
$ |
6,301,205 |
||
The accompanying notes are an integral part of the financial statements. | ||||
| ||
|
Vitarich Laboratories, Inc.
Statement of Income
For the Eight Months Ended August 30, 2004 |
||||
Sales, Net of Discounts |
$ |
10,891,005 |
||
Cost of Sales |
8,017,092 |
|||
Gross Profit |
2,873,913 |
|||
Operating Expenses: |
||||
General & Administrative |
1,267,876 |
|||
Selling Expenses |
208,204 |
|||
Total Operating Expenses |
1,476,080 |
|||
Income From Operations |
1,397,833 |
|||
Other Income (Expenses) |
||||
Interest Expense |
(62,233 |
) | ||
Interest Income |
481 |
|||
Capital Gain/Loss on Disposition of Fixed Assets |
(14,649 |
) | ||
Other (Expense) |
( 76,401 |
) | ||
Income Before Income Taxes |
1,321,432 |
|||
Provision for Income Tax |
||||
Current Taxes |
455,561 |
|||
Deferred Taxes |
34,176 |
|||
Total Income Taxes |
489,737 |
|||
Net Income |
$ |
831,695 |
||
The accompanying notes are an integral part of the financial statements. |
|
Number of Common Stock Shares Outstanding |
Common Stock Par Value |
Additional Paid-In Capital |
Retained Earnings |
||||||||||
Beginning Balance |
100 |
$ |
100 |
$ |
77 |
$ |
1,097,932 |
||||||
Net Income |
831,695 |
||||||||||||
|
|||||||||||||
Acquisition of Treasury Stock |
( 7 |
) |
( 7 |
) |
( 699,993 |
) | |||||||
Ending Balance |
93 |
$ |
93 |
$ |
77 |
$ |
1,299,634 |
| ||
|
Cash Flows from Operating Activities |
||||
Net Income |
$ |
831,695 |
||
Adjustments to reconcile net income to
net cash provided by operations |
||||
Depreciation |
123,158 |
|||
Loss on Disposal of Fixed Assets |
14,649 |
|||
Deferred Income Tax |
34,176 |
|||
Bad Debt Recoveries |
(248,000 |
) | ||
Write off of Loan Receivable - Affiliated Corporation |
17,229 |
|||
Loan Payable - NFLL Charge |
(109,959 |
) | ||
Changes in Assets and Liabilities |
||||
Decrease in Accounts Receivables |
1,180,797 |
|||
Increase in Inventory |
(2,233,002 |
) | ||
Increase in Other Receivable |
(8,457 |
) | ||
Decrease in Prepaid Assets |
102,798 |
|||
Increase in Deposit on Inventory |
(92,331 |
) | ||
Decrease in Other Deposits |
7,750 |
|||
Increase in Bank Overdraft |
161,604 |
|||
Increase in Accounts Payable |
432,106 |
|||
Decrease in Accrued Payroll & Payroll Taxes |
(94,466 |
) | ||
Increase in Accrued Income Taxes |
372,561 |
|||
Increase in Accounts Payable-Affiliated Corporations |
9,645 |
|||
Increase in Accrued Expenses & Other Current Liabilities |
72,010 |
|||
Net Cash provided by Operating Activities |
573,963 |
|||
Cash Flows from Investing Activities |
||||
|
||||
Purchases of Fixed Assets |
(536,711 |
) | ||
Loan Receivable-Shareholder |
(34,889 |
) | ||
Net cash used by Investing Activities |
(571,600 |
) | ||
Cash Flows from Financing Activities |
||||
Payments on Loan Payable-Affiliated Corporation |
(8,105 |
) | ||
Proceeds from Loan Payable-Shareholder |
2,274 |
|
Proceeds from Note Payable |
398,017 |
|||
Payments on Notes Payable |
(34,133 |
) | ||
Proceeds from Obligations Under Capital Leases |
364,905 |
|||
Payments on Obligations Under Capital Leases |
(95,394 |
) | ||
Acquisition of Treasury Stock |
(700,000 |
) | ||
|
||||
Net cash used by Financing Activities |
(72,436 |
) | ||
Net decrease in cash and cash
equivalents for the period |
(70,073 |
) | ||
Cash and Cash Equivalents at the beginning
of the period |
175,781 |
|||
Cash and Cash Equivalents at the end of the period |
$ |
105,708 |
||
Supplemental Disclosure of Cash Flows |
||||
Cash paid during the period for interest expense |
$ |
60,573 |
||
Cash paid during the period for income taxes |
$ |
83,000 |
||
The accompanying notes are an integral part of the financial statements. | ||||
|
Machinery & Equipment |
5 to 7 years |
Office Furniture and Fixtures |
5 to 7 years |
Leasehold Improvements |
20 years |
|
| |||
Inventory consists of the following: | |||
Raw Materials |
$ |
2,950,102 | |
Work in Process |
106,162 | ||
Finished Goods |
190,913 | ||
$ |
3,247,177 |
Accrued Interest |
$ |
1,660 |
||
Obligation to Fund Inventory Deposit |
109,000 |
|||
Accrued Vacation Pay |
40,685 |
|||
Other Accrued Expenses |
124,342 |
|||
$ |
275,687 |
Notes Payable as of August 30, 2004 consists of the following: |
Term Loan - Wachovia National Bank - The Company borrowed $ 80,873 in order to finance the acquisition of machinery and equipment. The term loan is payable in 84 monthly installments of $ 1,229 beginning October 11, 1998. The interest on the term loan is a variable rate calculated at Wall Street Journal Prime Rate plus .25% per annum. The loan is secured by specified machinery and equipment. The interest rate was 4.75% at August 30, 2004. |
Equipment Note - First Florida Bank - This note was used to fund the acquisition of diagnostic lab equipment which cost $115,000 The note provides for 60 monthly installments of $2,310 per month beginning November 10, 2002. The interest rate is 7.50% per annum. |
|
Term Loan - Key Bank - Company borrowed $148,111 in order to finance the companys liability insurance. The term loan is payable in December 2004 with interest only payments thru term. Interest rate was 5% as of August 30, 2004. |
Key Bank Line of Credit - In early 2004 Key Bank issued a line of credit for $400,000. This was used for the purchase of additional inventory products. The interest rate was 5% at August 30, 2004. |
Term Loan Wachovia Nat. Bank |
$ |
13,970 |
||
Equipment Note First Florida Bank |
77,816 |
|||
Term Loan Key Bank |
139,286 |
|||
Key Bank Line of Credit |
398,017 |
|||
$ |
629,089 |
|||
Current Portion |
574,281 |
|||
Notes Payable |
54,808 |
|||
|
||||
$ |
629,089 |
2006 |
$ |
24,080 |
||
2007 |
26,155 |
|||
2008 |
4,573 |
|||
$ |
54,808 |
|
Controlling Shareholder Leases |
Other Leases |
Total | ||||||||
12 months ended August 30, 2005 |
$ |
145,500 |
$ |
140,966 |
$ |
286,466 |
||||
12 months ended August 30, 2006 |
145,500 |
129,744 |
275,244 |
|||||||
12 months ended August 30, 2007 |
123,500 |
132,336 |
255,836 |
|||||||
12 months ended August 30, 2008 |
79,500 |
134,976 |
214,476 |
|||||||
12 months ended August 30, 2009 |
79,500 |
- |
79,500 |
|||||||
Subsequent Years |
- |
- |
- |
|||||||
Total |
$ |
573,500 |
$ |
538,022 |
$ |
1,111,522 |
|
Accounts Payable - Biotech Analytical Laboratories, Inc. | $ | 10,300 | ||
Accounts Payable - Vitarich Farms, Inc. | 57,870 | |||
Accounts Payable - Affiliated Corporations | $ | 68,170 |
|
Equipment Under Capital Leases | $ | 429,006 | ||
Less: Accumulated Depreciation | 130,687 | |||
$ | 298,319 |
Year ended August 30, 2005 | $ | 134,470 | ||
Year ended August 30, 2006 | 134,470 | |||
Year ended August 30, 2007 | 97,285 | |||
Year ended August 30, 2008 | 89,724 | |||
Year ended August 30, 2009 | 41,834 | |||
$ | 497,783 | |||
Less: Amount representing interest | $ | 79,707 | ||
Present value of minimum lease payments | $ | 418,076 |
|
Current |
Deferred |
|||||
Federal |
$ |
387,503 |
$ |
29,021 |
|||
State of Florida |
68,058 |
5,155 |
|||||
|
$ |
455,561 |
$ | 34,176 |
Accrued federal income taxes |
$ |
362,503 |
||
Accrued state income taxes |
62,058 |
|||
$ |
424,561 |
|
| ||
|
|
Vitarich Laboratories, Inc.
Balance Sheet
December 31, 2003 |
||||
ASSETS |
||||
Current Assets: |
||||
Cash |
$ |
175,781 |
||
Accounts receivable, net of allowance of $466,000 for doubtful accounts |
2,403,226 |
|||
Inventory |
1,014,175 |
|||
Other Pre-Paid Assets |
148,592 |
|||
Deposits on Inventory |
131,669 |
|||
3,873,443 |
||||
Property & Equipment: |
||||
Machinery & Equipment |
656,058 |
|||
Office Furniture & Fixtures |
104,708 |
|||
Leasehold Improvements |
184,682 |
|||
945,448 |
||||
Less accumulated depreciation |
(280,717 |
) | ||
664,731 |
||||
Loan Receivable Affiliated Corporation |
17,229 |
|||
Other Deposits |
66,080 |
|||
Total Assets |
$ |
4,621,483 |
||
Liabilities and Stockholders' Equity |
||||
Current Liabilities: |
||||
Accounts Payable |
$ |
1,887,521 |
||
Accrued Payroll & Payroll Taxes |
160,873 |
|||
Accrued Income Taxes |
52,000 |
|||
Accounts Payable - Affiliated Corporation |
58,525 |
|||
Accrued Expenses and Other Current Liabilities |
203,677 |
|||
Loan Payable - Affiliated Corporation |
8,105 |
|||
Loan Payable -Shareholder |
513,344 |
|||
Current Portion of Notes Payable |
161,573 |
|||
Current Portion of Obligations under Capital Leases |
63,507 |
|||
3,109,125 |
||||
The accompanying notes are an integral part of the financial statements. |
|
Other Liabilities |
||||
Notes Payable, net of Current portion |
213,591 |
|||
Obligations Under Capital Leases, net of Current portions |
85,058 |
|||
Deferred Tax |
115,600 |
|||
414,249 |
||||
Stockholders' Equity |
||||
Common Stock, $1 Par Value, |
||||
100 shares authorized, issued, and outstanding |
100 |
|||
Additional Paid-in-Capital |
77 |
|||
Retained Earnings |
1,097,932 |
|||
1,098,109 |
||||
Total Liabilities and Stockholders' Equity |
$ |
4,621,483 |
||
The accompanying notes are an integral part of the financial statements. |
||||
|
Vitarich Laboratories, Inc.
Statement of Income
For the Year Ended December 31, 2003 |
||||
Sales, Net of Discounts |
$ |
14,067,294 |
||
Cost of Sales |
10,252,403 |
|||
Gross Profit |
3,814,890 |
|||
Operating Expenses: |
||||
Selling Expenses |
445,312 |
|||
General & Administrative Expenses |
2,912,213 |
|||
Total Operating Expenses |
3,357,525 |
|||
Income From Operations |
457,366 |
|||
Other Income (Expenses) |
||||
Interest Income |
1,470 |
|||
Interest Expense |
(16,268 |
) | ||
Gain/Loss On Sale and Disposal of Fixed Assets |
1,673 |
|||
Income Before Income Taxes |
444,241 |
|||
Provision for Income Taxes |
||||
Current Taxes |
119,900 |
|||
Deferred Taxes |
50,431 |
|||
Total Taxes |
170,331 |
|||
Net Income |
$ |
273,910 |
||
The accompanying notes are an integral part of the financial statements. |
| ||
|
Number of |
Common |
Additional |
||||||||||||||
Common Stock |
Stock |
Paid-In |
Retained |
|||||||||||||
Shares Outstanding |
Par Value |
Capital |
Earnings |
Total |
||||||||||||
Beginning Balance |
100 |
$ |
100 |
$ |
77 |
$ |
824,022 |
$ |
824,199 |
|||||||
Net Income |
273,910 |
273,910 |
||||||||||||||
Shareholder Distributions |
||||||||||||||||
Ending Balance |
100 |
$ |
100 |
77 |
$ |
1,097,932 |
$ |
1,098,109 |
| ||
|
Cash Flows from Operating Activities |
||||
Net Income |
$ |
273,910 |
||
Adjustments to Reconcile net income to net cash provided by operations |
||||
Depreciation |
142,642 |
|||
Gain on Disposal of Fixed Assets |
(1,673 |
) | ||
Deferred income Tax |
50,431 |
|||
Provision for Bad Debt Expense |
41,512 |
|||
Change in assets and liabilities |
||||
Increase in Accounts Receivable |
(1,263,613 |
) | ||
Increase in Inventory |
(492,973 |
) | ||
Increase in Other Prepaid Assets |
(105,463 |
) | ||
Increase in Inventory Deposit |
(131,669 |
) | ||
Decrease in Prepaid Taxes |
51,002 |
|||
Increase in Other Deposits |
(50,480 |
) | ||
Increase in Accounts Payable |
921,977 |
|||
Decrease in Accrued Payroll & Payroll Taxes |
(205,419 |
) | ||
Increase in Accrued Income Taxes |
52,000 |
|||
Increase in Accounts Payable-Affiliated Corporations |
13,786 |
|||
Increase in Accrued Expenses & Other Current Liabilities |
9,837 |
|||
Net cash provided by operating activities |
(694,193 |
) | ||
Cash flows from investing activities |
||||
Loan receivable-affiliated corporation |
109,444 |
|||
Proceeds from sale of fixed assets |
113,303 |
|||
Purchase of fixed assets |
(265,854 |
) | ||
Net cash used by Investing Activities |
(43,107 |
) | ||
Cash flows from financing activities |
||||
|
||||
Proceeds from Loan Payable- Shareholder |
500,230 |
|||
Proceeds from Notes Payable |
150,000 |
|||
Payments on Notes Payable |
(32,918 |
) | ||
Proceeds from Capital Leases |
89,108 |
|||
Payments on Capital Leases |
(26,013 |
) | ||
Net cash used by financing activities |
680,407 |
|||
Net decrease in cash and cash equivalents for the period |
(56,893 |
) | ||
Cash and Cash Equivalents at the beginning of the year |
232,674 |
|||
Cash and Cash Equivalents at the end of the year |
$ |
175,781 |
||
Supplemental Disclosure of Cash Flow Information |
||||
Cash paid during the period for interest expense |
$ |
16,268 |
||
Cash paid during the period for income taxes |
$ |
119,900 |
||
The accompanying notes are an integral part of the financial statements. |
| ||
|
Machinery & Equipment |
3 to 10 years |
Office Furniture and Fixtures |
5 to 7 years |
Leasehold Improvements |
40 years |
|
Raw Materials |
$ |
845,849 |
|||
Work in Process and Finished Goods |
168,326 |
||||
$ |
1,014,175 |
Accrued Vacation Pay |
$ |
40,948 |
|||
Other Accrued Expenses |
162,729 |
||||
$ |
203,677 |
Notes Payable as of December 31, 2003 consists of the following: |
|
Term Loan - Wachovia National Bank - The Company borrowed $ 80,873 in order to finance the acquisition of machinery and equipment. The term loan is payable in 84 monthly installments of $ 1,229 beginning October 11, 1998. The interest on the term loan is a variable rate calculated at Wall Street Journal Prime Rate plus .25% per annum. The interest rate was 5% at December 31, 2003. The loan is secured by specified machinery and equipment. |
Equipment Note - First Florida Bank - This note was used to fund the acquisition of diagnostic lab equipment which cost $115,000. The note provides for 60 monthly installments of $2,310 per month beginning November 10, 2002. The interest rate is 7.50% per annum. |
Term Loan - Key Bank - Company borrowed $148,111 in order to finance the Companys liability insurance. The term loan is payable in May 2004 with interest only payments thru term. The interest rate was 5% at December 31, 2003. |
NFLI Note Payable |
$ |
109,959 |
||
Term Loan Wachovia Nat. Bank |
25,158 |
|||
Equipment Note First Florida Bank |
91,936 |
|||
Term Loan Key Bank |
148,111 |
|||
$ |
375,164 |
|||
Less Current portion |
161,573 |
|||
Total Notes Payable |
213,591 |
|||
$ |
375,164 |
2005 |
$ |
88,264 |
||
2006 |
74,178 |
|||
2007 |
43,219 |
|||
2008 |
7,930 |
|||
$ |
213,591 |
|
Controlling |
Other |
||||||
Shareholder |
Leases |
||||||
Leases |
|||||||
2004 |
$ |
66,000 |
$ |
118,460 |
|||
2005 |
66,000 |
122,400 |
|||||
2006 |
66,000 |
126,064 |
|||||
2007 |
27,500 |
42,432 |
|||||
2008 and Subsequent years |
0 |
0 |
|||||
$ |
225,500 |
$ |
409,356 |
|
Current |
Deferred | |||||
Federal |
$ |
101,000 |
$ |
43,371 | ||
State of Florida |
18,900 |
7,060 | ||||
$ |
119,900 |
$ |
50,431 |
Accrued federal income taxes |
$ |
36,000 |
||
Accrued State of Florida income taxes |
16,000 |
|||
$ |
52,000 |
| ||
|
|
|
Vitarich Laboratories, Inc.
Balance Sheet
December 31, 2002 | ||
ASSETS |
||||
Current Assets: |
||||
Cash |
$ |
232,674 |
||
Accounts receivable, net of allowance
of $460,839 for doubtful accounts |
1,154,819 |
|||
Inventory |
521,202 |
|||
Prepaid Income Taxes |
51,002 |
|||
Other Pre-Paid Assets |
43,129 |
|||
2,002,826 |
||||
Property & Equipment: |
||||
Machinery & Equipment |
614,160 |
|||
Office Furniture & Fixtures |
75,936 |
|||
Leasehold Improvements |
164,299 |
|||
854,395 |
||||
Less accumulated depreciation |
(201,246 |
) | ||
653,149 |
||||
Loan Receivable - Affiliated Corporation |
126,673 |
|||
Other Deposits |
15,600 |
|||
Total Assets |
$ |
2,798,248 |
||
Liabilities and Stockholder's Equity |
||||
Current Liabilities: |
||||
Accounts Payable |
$ |
965,544 |
||
Accrued Payroll & Payroll Taxes |
366,292 |
|||
Accounts Payable - Affiliated Corporation |
44,739 |
|||
Loan Payable - Affiliated Corporation |
8,105 |
|||
Accrued Expenses and Other Current Liabilities |
193,840 |
|||
Loan Payable -Shareholder |
13,114 |
|||
Current Portion of Notes Payable |
27,666 |
|||
Current Portion of Obligations under Capital Leases |
24,002 |
|||
1,643,302 |
||||
The accompanying notes are an integral part of the financial statements.
|
|
|
||||
Other Liabilities |
||||
Notes Payable, net of Current Portion |
230,416 |
|||
Obligations Under Capital leases, net of Current Portions |
61,468 |
|||
Deferred Taxes |
38,863 |
|||
330,747 |
||||
Stockholder's Equity |
||||
Common Stock, $1 Par Value, |
||||
100 shares authorized, 100 issued, and outstanding |
100 |
|||
Additional Paid -in-Capital |
77 |
|||
Retained Earnings |
824,022 |
|||
824,199 |
||||
Total Liabilities and Stockholder's Equity |
$ |
2,798,248 |
||
The accompanying notes are an integral part of the financial statements. |
|
|
||||
Sales, Net of Discounts |
$ |
14,340,620 |
||
Cost of Sales |
10,106,498 |
|||
Gross Profit |
4,234,122 |
|||
Operating Expenses: |
||||
Selling Expenses |
306,149 |
|||
General & Administrative Expenses |
3,576,138 |
|||
Total Operating Expenses |
3,882,287 |
|||
Income From Operations |
351,835 |
|||
Other Income (Expenses) |
||||
Interest Income |
11,207 |
|||
Interest Expense |
(42,602 |
) | ||
Gain/Loss On Sale and Disposal of Fixed Assets |
11,360 |
|||
Income Before Income Taxes |
331,800 |
|||
Provision for Income Taxes |
||||
Current Taxes |
83,000 |
|||
Deferred Taxes |
24,219 |
|||
Total Taxes |
107,219 |
|||
Net Income |
$ |
224,581 |
| ||
|
Number of Common Stock Shares Outstanding |
Common Stock Par Value |
Additional Paid-In Capital |
Retained
Earnings |
Total |
||||||||||||
Beginning Balance |
100 |
$ |
100 |
$ |
77 |
$ |
599,441 |
$ |
599,618 |
|||||||
Net Income |
224,581 |
224,581 |
||||||||||||||
Shareholder Distributions |
||||||||||||||||
Ending Balance |
100 |
$ |
100 |
$ |
77 |
$ |
824,022 |
$ |
824,199 |
| ||
|
Vitarich Laboratories, Inc.
Statement of Cash Flows
For the Twelve Months Ended December 31, 2002 |
||||
Cash Flows from Operating Activities |
||||
Net Income |
$ |
224,581 |
||
Non cash (income) expense included in net income:
Depreciation and amortization
Provision for bad debt expense, net of direct write-off
Deferred income tax |
76,801
122,044
24,219 |
|||
Change in assets and liabilities
(Increase) decrease in trade receivables
(Increase) decrease in inventory
(Increase) decrease in other assets
Increase (decrease) in accounts payable
Increase (decrease) in accrued expenses |
406,923
26,964
(128,753)
(334,793)
186,282 |
|||
Net cash provided by (used in) Operations |
604,268 |
|||
Cash Flows from Investing Activities
Purchases of property and equipment |
(409,320 |
) | ||
Net cash provided by (used in) investing activities |
(409,320 |
) | ||
Cash Flows from Financing Activities |
||||
Proceeds from Loan Payable Shareholder
Long Term Debt |
(331,358
(3,146 |
)
) | ||
Net cash provided by (used in) financing activities |
(334,504 |
) | ||
Net Increase (Decrease) in Cash |
(139,557 |
) | ||
Summary |
||||
Cash Balance at End of Period
Cash Balance at Beginning of Period |
232,674
372,231 |
|||
|
||||
Net Increase (Decrease) in Cash |
$ |
(139,557 |
) | |
Supplemental Disclosure of Cash Flows
Interest Paid |
$ |
46,602 |
||
Income Taxes Paid |
$ |
225,000 |
||
| ||
|
Machinery & Equipment |
3 to 10 years |
Office Furniture and Fixtures |
5 to 7 years |
Leasehold Improvements |
40 years |
Raw Materials |
$ |
432,700 |
||
Work in Process and Finished Goods |
88,502 |
|||
$ |
521,202 |
Accrued Vacation Pay |
$ |
43,840 |
||
Other Accrued Expenses |
150,000 |
|||
$ |
193,840 |
Notes Payable as of December 31, 2002 consists of the following: |
|
Term Loan - Wachovia National Bank - The Company borrowed $ 80,873 in order to finance the acquisition of machinery and equipment. The term loan is payable in 84 monthly installments of $ 1,229 beginning October 11, 1998. The interest on the term loan is a variable rate calculated at Wall Street Journal Prime Rate plus .25% per annum. The interest rate was 4.5% at December 31, 2002. The loan is secured by specified machinery and equipment. |
Equipment Note - First Florida Bank - This note was used to fund the acquisition of diagnostic lab equipment which cost $115,000. The note provides for 60 monthly installments of $2,310 per month beginning November 10, 2002. The interest rate is 7.50% per annum. |
NFLL Note Payable |
$ |
109,959 |
||
Term Loan Wachovia Nat. Bank |
38,859 |
|||
Equipment Note First Florida Bank |
109,264 |
|||
$ |
258,082 |
|||
Less Current portion |
27,666 |
|||
Notes Payable |
230,416 |
|||
$ |
258,082 |
2004 |
$ |
33,556 |
||
2005 |
28,859 |
|||
2006 |
29,782 |
|||
2007 |
27,259 |
|||
2008 and subsequent years |
110,960 |
|||
$ |
230,416 |
Controlling |
Other |
||||||
Shareholder |
Leases |
||||||
Leases |
|||||||
2003 |
$ |
66,000 |
$ |
113,900 |
|||
2004 |
66,000 |
118,460 |
|||||
2005 |
66,000 |
122,400 |
|||||
2006 |
66,000 |
125,884 |
|||||
2007 and Subsequent years |
27,500 |
42,432 |
|||||
$ |
291,500 |
$ |
523,076 |
|
Current |
Deferred |
||||||
Federal |
$ |
71,000 |
$ |
20,718 |
|||
State of Florida |
12,000 |
3,501 |
|||||
$ |
83,000 |
$ |
24,219 |
Prepaid federal income taxes |
$ |
50,616 |
||
Prepaid State of Florida income taxes |
386 |
|||
$ |
51,002 |
Equipment Under Capital Leases |
$ |
119,260 |
||
Less: Accumulated Depreciation |
29,284 |
|||
$ |
89,976 |
Year ended December 31, 2003 |
$ |
31,692 |
||
Year ended December 31, 2004 |
31,692 |
|||
Year ended December 31, 2005 |
34,298 |
|||
Year ended December 31, 2006 |
0 |
|||
$ |
97,682 |
|||
Less: Amount representing interest |
12,212 |
|||
Present value of minimum lease payments |
$ |
85,470 |
|
(b) | Pro Forma Financial Information |
| ||
|
AI as |
VLI as |
Pro Forma |
Consolidated |
||||||||||
Reported (A) |
Reported (B) |
Adjustments |
Pro Forma |
||||||||||
Net sales |
$ |
6,780,000 |
$ |
14,067,000 |
-- |
$ |
20,847,000 |
||||||
Cost of goods sold |
5,184,000 |
10,252,000 |
-- |
15,436,000 |
|||||||||
Gross Profit |
1,596,000 |
3,815,000 |
5,411,000 |
||||||||||
Selling, general and
administrative expenses |
1,912,000 |
3,358,000 |
(1,389,000)(1)
400,000(2)
833,000(3)
360,000(4) |
|
5,474,000 |
||||||||
(Loss) income from
operations |
(316,000 |
) |
457,000 |
204,000 |
(63,000 |
) | |||||||
Interest expense |
47,000 |
16,000 |
-- |
63,000 |
|||||||||
Other income |
51,000 |
3,000 |
-- |
54,000 |
|||||||||
(Loss) income from
continuing operations
before income taxes |
(312,000 |
) |
444,000 |
(204,000 |
) |
(72,000 |
) | ||||||
Income tax (benefit)
provision |
(289,000 |
) |
170,000 |
(82,000)(5) |
|
(201,000 |
) | ||||||
(Loss) income from
continuing operations |
($23,000 |
) |
$ |
274,000 |
($122,000 |
) |
$ |
129,000 |
|||||
Earnings (loss) per share(6): |
|||||||||||||
Basic - continuing operations |
($0.02 |
) |
$ |
0.06 |
|||||||||
Diluted - continuing operations |
($0.02 |
) |
$ |
0.06 |
(A) | Report on Form 10-KSB filed on April 27, 2004. |
(B) | Report of Independent Accountants see Item 9.01(a) herein. |
(1) | To adjust for the post closing revision of contractual executive compensation program. |
(2) | To adjust for the amortization of the purchase accounting valuation of $2.0 million for non- contractual customer relationships which is being amortized over five years. |
(3) | To adjust for the amortization of the purchase accounting valuation of $2.5 million for proprietary formulas which is being amortized over three years. |
(4) | To adjust for amortization for the purchase accounting valuation of $1.8 million for the non-compete agreement with the seller which is being amortized over the life of the five-year contract. |
(5) | To reflect the tax impact, assuming an effective tax rate of 40% arising from the change in pretax income from net pro forma adjustments. |
(6) | Assumes 825,000 shares issued in connection with the transaction were outstanding for the entire period in calculating consolidated pro forma earnings per share. |
| ||
|
AI as |
|
Pro Forma |
Consolidated |
||||||||||
Reported (C) |
VLI (D) |
Adjustments |
Pro Forma |
||||||||||
Net sales |
$ |
3,634,000 |
$ |
8,261,000 |
-- |
$ |
11,895,000 |
||||||
Cost of goods sold |
3,214,000 |
6,013,000 |
-- |
9,227,000 |
|||||||||
Gross profit |
420,000 |
2,248,000 |
2,668,000 |
||||||||||
Selling, general and
administrative expenses |
1,478,000 |
953,000 |
$
|
(5,000)(1)
200,000(2)
417,000(3)
180,000(4) |
|
3,223,000 |
|||||||
Impairment loss |
1,942,000 |
-- |
-- |
1,942,000 |
|||||||||
Loss from operations |
(3,000,000 |
) |
1,295,000 |
792,000 |
(2,497,000 |
) | |||||||
Interest expense |
30,000 |
27,000 |
-- |
57,000 |
|||||||||
Other income |
55,000 |
68,000 |
-- |
123,000 |
|||||||||
Loss from continuing
operations before income taxes |
(2,975,000 |
) |
1,336,000 |
792,000 |
(2,431,000 |
) | |||||||
Income tax benefit (provision) |
(864,000 |
) |
519,000 |
(317,000)(5) |
|
(662,000 |
) | ||||||
Loss from continuing
operations |
($2,111,000 |
) |
$ |
817,000 |
($475,000 |
) |
($1,769,000 |
) | |||||
Basic and diluted loss per share(6): |
|||||||||||||
Basic and Diluted - |
|||||||||||||
continuing operations |
($1.17 |
) |
($0.67 |
) |
(C) | Report on Form 10-QSB filed on September 14, 2004. |
(D) | VLI unaudited internally prepared results of operations are for the six months ended June 30, 2004. |
(1) | To adjust for the post closing revision of contractual executive compensation program. |
(2) | To adjust for the amortization of the purchase accounting valuation of $2.0 million for non-contractual customer relationships which is being amortized over five years. |
(3) | To adjust for the amortization of the purchase accounting valuation of $2.5 million for proprietary formulas which is being amortized over three years. |
(4) | To adjust for the amortization of the purchase accounting valuation of $1.8 million for the non-compete agreement with the Seller which is being amortized over the life of the five year contract. |
(5) | To reflect the tax impact, assuming an effective tax rate of 40%, arising from the change in pretax income from net pro forma adjustments. |
(6) | Assumes 825,000 shares issued in connection with the transaction were outstanding for the entire period in calculating consolidated pro forma basic and diluted loss per share. |
| ||
|
AI as |
|
Pro Forma |
Consolidated |
||||||||||
Reported (E) |
VLI (F) |
Adjustments |
Pro Forma |
||||||||||
CURRENT ASSETS: |
($6,050,000)(1) |
|
|||||||||||
Cash and cash equivalents |
$ |
6,704,000 |
$ |
202,000 |
(600,000)(2) |
|
$ |
256,000 |
|||||
Accounts receivable |
1,035,000 |
2,109,000 |
3,144,000 |
||||||||||
Escrowed cash |
601,000 |
-- |
601,000 |
||||||||||
Estimated earnings in excess
of billings |
538,000 |
-- |
538,000 |
||||||||||
Inventory |
-- |
2,712,000 |
2,712,000 |
||||||||||
Prepaid expenses and other current
assets |
345,000 |
69,000 |
414,000 |
||||||||||
TOTAL CURRENT ASSETS |
9,223,000 |
5,092,000 |
(6,650,000 |
) |
7,665,000 |
||||||||
Property and equipment, net |
1,779,000 |
1,072,000 |
2,851,000 |
||||||||||
Contractual customer
relationships |
616,000 |
-- |
616,000 |
||||||||||
Non-contractual customer
relationships |
2,000,000(3) |
|
2,000,000 |
||||||||||
Proprietary formulas |
2,500,000(4) |
|
2,500,000 |
||||||||||
Non-compete agreement |
1,800,000(5) |
|
1,800,000 |
||||||||||
Trade name |
224,000 |
-- |
224,000 |
||||||||||
Goodwill |
940,000 |
-- |
6,086,000(6) |
|
7,026,000 |
||||||||
TOTAL ASSETS |
$ |
12,782,000 |
$ |
6,164,000 |
$ |
5,736,000 |
$ |
24,682,000 |
|||||
CURRENT LIABILITIES: |
|||||||||||||
Accounts payable |
$ |
374,000 |
$ |
1,994,000 |
$ |
2,368,000 |
|||||||
Billings in excess of estimated
earnings |
2,000 |
-- |
2,000 |
||||||||||
Accrued expenses |
308,000 |
713,000 |
1,021,000 |
||||||||||
Deferred income tax liability |
181,000 |
-- |
181,000 |
||||||||||
Line of Credit |
-- |
495,000 |
495,000 |
||||||||||
Current portion of long-term debt |
894,000 |
487,000 |
1,381,000 |
||||||||||
TOTAL CURRENT LIABILITIES |
1,759,000 |
3,689,000 |
5,448,000 |
||||||||||
Deferred income tax liability |
202,000 |
116,000 |
(2,520,000)(7) |
|
2,838,000 |
||||||||
Long-term debt |
62,000 |
443,000 |
505,000 |
||||||||||
STOCKHOLDERS EQUITY |
|||||||||||||
Common stock par value $.15
per share 12,000,000 shares
authorized - 1,806,046 issued at
July 31, 2004 and January 31,
2004 and 1,802,813 shares
outstanding at July 31,
2004 and January 31, 2004 |
270,000 |
-- |
(124,000)(1) |
|
394,000 |
||||||||
Warrants outstanding |
849,000 |
-- |
849,000 |
||||||||||
Additional paid-in capital |
14,121,000 |
-- |
(5,008,000)(1) |
|
19,129,000 |
||||||||
Accumulated deficit retained earnings |
(4,448,000 |
) |
1,916,000 |
1,916,000(1) |
|
(4,448,000 |
) | ||||||
Treasury stock at cost: 3,233
shares at July 31, 2004 and
January 31, 2004 |
(33,000 |
) |
-- |
-- |
(33,000 |
) | |||||||
TOTAL STOCKHOLDERS EQUITY |
10,759,000 |
1,916,000 |
(3,216,000 |
) |
15,891,000 |
||||||||
TOTAL LIABILITIES AND
STOCKHOLDERS EQUITY |
$ |
12,782,000 |
$ |
6,164,000 |
($5,736,000 |
) |
$ |
24,682,000 |
|
(E) |
Report on Form 10-QSB filed on September 14, 2004. | |
(F) |
VLIs unaudited internally prepared balance sheet is as of June 30, 2004. | |
(1) |
To adjust for the purchase of VLI using cash of $6,050,000 and 825,000 shares issued for an aggregate purchase price of $11,183,000. | |
(2) |
To record estimated costs associated with legal, accounting and other fees incurred to consummate the acquisition of VLI. | |
(3) |
To adjust for the purchase accounting valuation of $2.0 million for non-contractual customer relationships. | |
(4) |
To adjust for the purchase accounting valuation of $2.5 million for proprietary formulas. | |
(5) |
To adjust for the purchase accounting valuation of $1.8 million for non-compete agreement. | |
(6) |
To adjust for the purchase accounting valuation of $6,086,000 for goodwill. | |
(7) |
To adjust for deferred tax liabilities related to the purchase accounting valuation of non-contractual customer relationships, not-to-compete agreement and proprietary formulas. A rate of 40% is assumed. |
| ||
|
2.1 | Agreement and Plan of Merger, dated as of August 31, 2004, by and between Kevin J. Thomas, Vitarich Laboratories, Inc., Argan, Inc. and AGAX/VLI Acquisition Corporation (exhibits and schedules to the Agreement and Plan of Merger are omitted from this filing, but will be filed with the Commission supplementally upon request) |
10.1 | Registration Rights Agreement, dated as of August 31, 2004, by and among Argan, Inc. and Kevin J. Thomas |
10.2 | Employment Agreement, dated as of August 31, 2004, by and between AGAX/VLI Acquisition Corporation and Kevin J. Thomas |
10.3 | Third Amendment to Financing and Security Agreement, dated as of August 31, 2004, by the among Argan, Inc., Southern Maryland Cable, Inc., and AGAX/VLI Acquisition Corporation, as borrowers, and Bank of America, N.A., as lender |
10.4 | Amended and Restated Revolving Credit Note, dated August 31, 2004, in the amount of $3,500,000, by Argan, Inc., Southern Maryland Cable, Inc., and AGAX/VLI Acquisition Corporation, as borrowers, in favor of Bank of America, N.A., as lender |
10.5 | First Amendment to Term Note, dated as of June 29, 2004, by and among Argan, Inc., and Southern Maryland Cable, Inc., as borrowers, and Bank of America, N.A., as lender |
10.6 | Additional Borrowers Joinder Supplement, dated as of August 31, 2004, by and among Argan, Inc., the other Existing Borrowers (as such term is defined in the agreement) and AGAX/VLI Acquisition Corporation, as borrowers, and Bank of America, N.A., as lender |
|
99.1 | Press Release of Argan, Inc., dated September 1, 2004, announcing the acquisition of Vitarich Laboratories, Inc. |
ARGAN, INC. | ||
|
|
|
Date: November 12, 2004 | By: | /s/ Rainer H. Bosselmann |
Rainer H. Bosselmann | ||
Chairman of the Board and
Chief Executive Officer |
|